false
0001819576
0001819576
2023-11-07
2023-11-07
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 7, 2023
LIQUIDIA CORPORATION |
(Exact name of registrant as specified in its charter) |
|
|
|
Delaware |
001-39724 |
85-1710962 |
(State or other jurisdiction
of incorporation) |
(Commission
File Number) |
(IRS Employer
Identification No.) |
|
|
|
419 Davis Drive, Suite 100, Morrisville, North Carolina |
27560 |
(Address of principal executive offices) |
(Zip Code) |
Registrant’s telephone number, including
area code: (919) 328-4400
(Former name or former address, if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common stock |
LQDA |
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 |
Results of Operations and Financial Condition. |
On November 7, 2023, Liquidia Corporation, a Delaware
corporation, issued a press release announcing its financial results for the quarter ended September 30, 2023, and also provided a corporate
update. A copy of the press release is furnished herewith as Exhibit 99.1.*
Item 9.01 |
Financial Statements and Exhibits. |
(d)
* The information in Item 2.02 of this Form 8-K shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or
otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities
Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
November 7, 2023 |
Liquidia Corporation |
|
|
|
By: |
/s/ Michael Kaseta |
|
|
Name: Michael Kaseta |
|
|
Title: Chief Financial Officer |
Exhibit 99.1
Liquidia
Corporation Reports Third Quarter 2023 Financial Results and Provides Corporate Update
| · | Oral
arguments in appeal of ‘793 PTAB decision set for December 4, 2023 |
| · | PDUFA
goal date to add PH-ILD indication to YUTREPIA label is January 24, 2024 |
| · | Hired
sales force in preparation of potential positive legal and regulatory outcomes |
MORRISVILLE, N.C., November 7,
2023 - Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial results for the third quarter
ended September 30, 2023. The Company will host a webcast at 8:30 a.m. ET to discuss the financial results and provide a corporate update.
Dr. Roger Jeffs, Liquidia’s
Chief Executive Officer, said: “We continue to make great strides in advancing our mission to help patients with pulmonary
hypertension breathe easier and live longer. We are looking forward to upcoming key events that will help unlock the value of
YUTREPIA® (treprostinil) inhalation powder, with pivotal legal arguments set in early December and potential label
expansion of YUTREPIA for PH-ILD in late January. In anticipation of potential successful resolution of the ongoing legal dispute
with United Therapeutics and receiving final FDA approval, we have expanded our top-tier sales force, all of whom are deeply skilled
in the commercialization of rare disease products. If successful, we look forward to promoting the benefits of YUTREPIA’s
unmatched product profile, specifically its tolerability, titratability, and durability, all delivered via a patient-friendly
low-effort device enabled by our proprietary PRINT technology.”
Corporate Updates
Received
PDUFA goal date to add PH-ILD indication to YUTREPIA label. The U.S. Food and Drug Administration (FDA) accepted the amendment to
the New Drug Application (NDA) for YUTREPIA to add the indication of pulmonary hypertension associated
with interstitial lung disease (PH-ILD) to the label and has set a Prescription Drug User Fee Act
(PDUFA) goal date of January 24, 2024. If approved, YUTREPIA would be indicated for the treatment of both pulmonary arterial hypertension
(PAH) and PH-ILD, though final approval of the PH-ILD indication cannot occur until the new clinical investigation exclusivity granted
to Tyvaso® expires on March 31, 2024. Concurrent with this amendment, Liquidia submitted a paragraph IV certification
indicating that the patents listed for Tyvaso® in the FDA’s publication commonly known as the Orange Book are invalid
and/or not infringed by YUTREPIA. In September 2023, United Therapeutics (UTHR) filed a second complaint for patent infringement against
the Company under the Hatch-Waxman Act in the U.S. District Court for the District of Delaware (District Court), asserting infringement
of U.S. Patent No. 10,716,793 (‘793 Patent). This second complaint is tied to the
same ‘793 patent previously ruled invalid by Patent Trial and Appeal Board (PTAB).
Oral arguments for appeal of PTAB
ruling of ‘793 Patent invalidity scheduled for December 4, 2023. Final regulatory approval of YUTREPIA is currently barred by
an order from earlier Hatch-Waxman proceedings in the District Court in which the ‘793 Patent was found to be valid and infringed.
However, in a parallel proceeding before the PTAB, the ‘793 Patent was found to be invalid. If the PTAB’s decision is affirmed
by the Court of Appeals for the Federal Circuit (CAFC), then the PTAB’s decision would override the decision from the District
Court proceeding, thereby creating the opportunity for the Company to seek final FDA approval for YUTREPIA. Once argued, the CAFC could
rule within a few days, in the case of summary affirmance, or within a few months after oral argument if a full written opinion is issued.
Additionally, if the CAFC upholds the PTAB decision in Liquidia’s favor, then such ruling would have precedential effect in the
second lawsuit recently filed by UTHR alleging infringement of the ‘793 Patent in connection with the amendment of YUTREPIA’s
NDA to add the PH-ILD indication.
Fully transitioned clinical development
of L606 from Pharmosa to Liquidia for the North American territory. In June, Liquidia acquired an exclusive license to develop and
commercialize L606, an inhaled, sustained-release formulation of treprostinil currently being evaluated in a Phase 3 open-label clinical
trial for the treatment of PAH and PH-ILD. Compared to current inhaled options, L606 offers potential advantages of more consistent drug
exposure over 24 hours, including during sleeping hours, with twice-daily dosing and improved tolerability via a modern, next-gen nebulizer.
Liquidia has assumed full responsibility for the investigational new drug (IND) and is preparing for a Type C meeting with the FDA in
December to discuss the registration pathway for PAH and PH-ILD.
Third
Quarter 2023 Financial Results
Cash
totaled $76.2 million as of September 30, 2023, compared to $93.3 million as of December 31, 2022.
Revenue
was $3.7 million for the three months ended September 30, 2023, compared to $3.2 million for the three months ended September 30,
2022. Revenue related primarily to the promotion agreement between Liquidia PAH and Sandoz Inc, sharing profit derived from the sale
of Sandoz’s substitutable generic treprostinil injection (Treprostinil Injection) in the United States (the Promotion Agreement).
The increase from the prior year was primarily due to favorable gross-to-net managed care and chargeback adjustments offset by the impact
of lower sales quantities as compared to the same period in the prior year.
Cost
of revenue was $0.6 million for the three months ended September 30, 2023, compared to $0.7 million for the three months ended September
30, 2022. Cost of revenue related to the Promotion Agreement as noted above. The decrease from the
prior year was primarily due to lower intangible asset amortization due to an extension of the term of the Promotion Agreement during
the fourth quarter of 2022.
Research
and development expenses were $7.4 million for the three months ended September 30, 2023, compared to $4.5 million for the three
months ended September 30, 2022. The increase of $2.9 million or 65% was primarily due to a $1.5 million increase in expenses related
to our YUTREPIA program driven by higher manufacturing and pre-launch commercial supply costs, a $0.7 million increase in consulting
and personnel expenses related to higher headcount, and a $0.4 million increase in clinical expenses related to our L606 open label study.
General
and administrative expenses were $10.6 million for the three months ended September 30, 2023, compared to $6.7 million for the three
months ended September 30, 2022. The increase of $3.9 million or 57% was primarily due to a $1.4 million increase in legal fees related
to our ongoing YUTREPIA-related litigation, a $0.9 million increase in consulting and personnel expenses in preparation for the potential
commercialization of YUTREPIA, a $0.7 million increase in commercial expenses, and a $0.6 million increase in stock-based compensation
expense.
Total other expense, net was
$0.9 million for the three months ended September 30, 2023, compared with $0.3 million for the three months ended September 30, 2022.
The increase of $0.6 million was driven by $1.1 million higher interest expense attributable to the higher borrowings under the Revenue
Interest Financing Agreement with HealthCare Royalty Partners as compared to balances outstanding under the Amended
and Restated Loan and Security Agreement with Silicon Valley Bank and offset by a $0.5 million increase in interest income attributable
to higher money market yields.
Net loss for the three months
ended September 30, 2023, was $15.8 million, or $0.24 per basic and diluted share, compared to a net loss of $9.1 million, or $0.14 per
basic and diluted share, for the three months ended September 30, 2022.
About YUTREPIA™(treprostinil)
inhalation powder
YUTREPIA is
an investigational, inhaled dry powder formulation of treprostinil delivered through a convenient, low-resistance, palm-sized device.
On November 5, 2021, the FDA issued a tentative approval for YUTREPIA for the treatment of pulmonary arterial hypertension (PAH) to improve
exercise ability in adult patients with New York Heart Association (NYHA) Functional Class II-III symptoms. In July 2023, Liquidia filed
an amendment to its NDA for YUTREPIA, seeking to add pulmonary hypertension with interstitial lung disease (PH-ILD) to the label. The
FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of January 24, 2024 for the amendment. Previously, the FDA has confirmed
that YUTREPIA may add the treatment of PH-ILD to the label for YUTREPIA without additional clinical studies. YUTREPIA was designed using
Liquidia’s PRINT® technology, which enables the development of drug particles that are precise and uniform in size,
shape, and composition, and that are engineered for enhanced deposition in the lung following oral inhalation. Liquidia has completed
INSPIRE, or Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil, an open-label, multi-center phase
3 clinical study of YUTREPIA in patients diagnosed with PAH who are naïve to inhaled treprostinil or who are transitioning from
Tyvaso® (nebulized treprostinil). YUTREPIA was previously referred to as LIQ861 in investigational studies.
About L606
(liposomal treprostinil) inhalation suspension
L606 is an
investigational, sustained-release formulation of treprostinil administered twice-daily with a short-duration next-generation nebulizer.
The L606 suspension uses Pharmosa Biopharm’s proprietary liposomal formulation to encapsulate treprostinil which can be released
slowly at a controlled rate into the lung, enhancing drug exposure over an extended period of time and reducing local irritation of the
upper respiratory tract. L606 is currently being evaluated in an open-label study in the United States for treatment of pulmonary arterial
hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) with a planned pivotal study for the
treatment of PH-ILD.
About Treprostinil
Injection
Treprostinil
Injection is the first-to-file, fully substitutable generic treprostinil for parenteral administration. Treprostinil Injection contains
the same active ingredient, same strengths, same dosage form and same inactive ingredients as Remodulin® (treprostinil)
and is offered to patients and physicians with the same level of service and support, but at a lower price than the branded drug. Liquidia
PAH promotes the appropriate use of Treprostinil Injection for the treatment of PAH in the United States in partnership with its commercial
partner, who holds the Abbreviated New Drug Application (ANDA) with the FDA.
About pulmonary
arterial hypertension (PAH)
Pulmonary arterial
hypertension (PAH) is a rare, chronic, progressive disease caused by hardening and narrowing of the pulmonary arteries that can lead
to right heart failure and eventually death. Currently, an estimated 45,000 patients are diagnosed and treated in the United States.
There is currently no cure for PAH, so the goals of existing treatments are to alleviate symptoms, maintain or improve functional class,
delay disease progression, and improve quality of life.
About pulmonary
hypertension associated with interstitial lung disease (PH-ILD)
Pulmonary hypertension
(PH) associated with interstitial lung disease (ILD) includes a diverse collection of up to 150 different pulmonary diseases, including
interstitial pulmonary fibrosis, chronic hypersensitivity pneumonitis, connective tissue disease related ILD, and chronic pulmonary fibrosis
with emphysema (CPFE) among others. Any level of PH in ILD patients is associated with poor 3-year survival. A current estimate of PH-ILD
prevalence in the United States is greater than 60,000 patients, though population growth in many of these underlying ILD diseases is
not yet known due to factors including underdiagnosis and lack of approved treatments until March 2021, when inhaled treprostinil was
first approved for this indication.
About Liquidia
Corporation
Liquidia Corporation
is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications
of its PRINT® Technology. The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc.
and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary
arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Liquidia Technologies is also
developing L606, an investigational liposomal formulation of treprostinil administered twice-daily with a short-duration next-generation
nebulizer, for use in North America. Liquidia PAH provides the commercialization for pharmaceutical products to treat pulmonary disease,
such as generic Treprostinil Injection. For more information, please visit www.liquidia.com.
Remodulin® and Tyvaso®
are registered trademarks of United Therapeutics Corporation.
Cautionary
Statements Regarding Forward-Looking Statements
This press
release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements
contained in this press release other than statements of historical facts, including statements regarding our future results of operations
and financial position, our strategic and financial initiatives, our business strategy and plans and our objectives for future operations,
are forward-looking statements. Such forward-looking statements, including statements regarding clinical trials, clinical studies and
other clinical work (including the funding therefor, anticipated patient enrollment, safety data, study data, trial outcomes, timing
or associated costs), regulatory applications and related submission contents and timelines, including the potential for final FDA approval
of the NDA for YUTREPIA, the timeline or outcome related to patent litigation in the U.S. District Court for the District of Delaware
or inter partes review proceedings conducted at the PTAB, including appeals of decisions in any such proceedings, the issuance
of patents by the USPTO and our ability to execute on our strategic or financial initiatives, involve significant risks and uncertainties
and actual results could differ materially from those expressed or implied herein. The favorable decisions of the PTAB with respect to
the ’793 patent is not determinative of the outcome of the appeal of the decision. The words “anticipate,” “believe,”
“continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,”
“potential,” “predict,” “project,” “should,” “target,” “would,”
and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on
our current expectations and projections about future events and financial trends that we believe may affect our financial condition,
results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking
statements are subject to a number of risks discussed in our filings with the SEC, including the impact of the coronavirus (COVID-19)
outbreak on our Company and our financial condition and results of operations, as well as a number of uncertainties and assumptions.
Moreover, we operate in a very competitive and rapidly changing environment and our industry has inherent risks. New risks emerge from
time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business
or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any
forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events discussed in this press
release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking
statements. Nothing in this press release should be regarded as a representation by any person that these goals will be achieved, and
we undertake no duty to update our goals or to update or alter any forward-looking statements, whether as a result of new information,
future events or otherwise.
Contact
Information
Media & Investors:
Jason Adair
Chief Business Officer
919.328.4400
jason.adair@liquidia.com
Liquidia Corporation
Select Consolidated Balance Sheet
Data
(in thousands)
| |
September 30, | | |
December 31, | |
| |
2023 | | |
2022 | |
Cash and cash equivalents | |
$ | 76,225 | | |
$ | 93,283 | |
Total assets | |
$ | 111,641 | | |
$ | 129,198 | |
Total liabilities | |
$ | 63,635 | | |
$ | 38,776 | |
Accumulated deficit | |
$ | (401,648 | ) | |
$ | (350,596 | ) |
Total stockholders’ equity | |
$ | 48,006 | | |
$ | 90,422 | |
Liquidia Corporation
Consolidated Statements of Operations
and Comprehensive Loss
(in thousands, except share and
per share amounts)
| |
Three Months Ended September 30, | |
| |
2023 | | |
2022 | |
Revenue | |
$ | 3,678 | | |
$ | 3,165 | |
Costs and expenses: | |
| | | |
| | |
Cost of revenue | |
| 570 | | |
| 740 | |
Research and development | |
| 7,440 | | |
| 4,512 | |
General and administrative | |
| 10,559 | | |
| 6,744 | |
Total costs and expenses | |
| 18,569 | | |
| 11,996 | |
Loss from operations | |
| (14,891 | ) | |
| (8,831 | ) |
Other income (expense): | |
| | | |
| | |
Interest income | |
| 862 | | |
| 359 | |
Interest expense | |
| (1,761 | ) | |
| (620 | ) |
Loss on extinguishment of debt | |
| — | | |
| — | |
Total other expense, net | |
| (899 | ) | |
| (261 | ) |
Net loss and comprehensive loss | |
$ | (15,790 | ) | |
$ | (9,092 | ) |
Net loss per common share, basic and diluted | |
$ | (0.24 | ) | |
$ | (0.14 | ) |
Weighted average common shares outstanding, basic and diluted | |
| 64,857,508 | | |
| 64,458,741 | |
v3.23.3
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Liquidia (NASDAQ:LQDA)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Liquidia (NASDAQ:LQDA)
Historical Stock Chart
Von Mai 2023 bis Mai 2024